ArticleFrontiers in oncology2026
Case series analysis of immunophenotypic evolution during recurrence of low-grade endometrial stromal sarcoma: implications for molecular stability and clinical management.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the pathological morphology, immunophenotype, and molecular genetic characteristics of recurrent low-grade endometrial stromal sarcoma (LG-ESS) through the analysis of paired primary and recurrent tumor samples. Methods: A single-center retrospective analysis was conducted using the clinical data, pathological morphology, immunohistochemical results of estrogen receptor, progesterone receptor (PR), CD10, Ki-67, and fluorescence Results: Patients' ages ranged from 22 to 34 years. All cases showed consistent Conclusion: This case series indicates that core driver gene rearrangements remain stable during recurrence in LG-ESS, whereas immunophenotypic evolution may occur in some cases. These preliminary findings suggest that the re-evaluation of biomarkers such as hormone receptors at recurrence may provide valuable guidance for individualized treatment selection (e.g., hormonal therapy). Given the characteristic tendency for late recurrence in LG-ESS, long-term follow-up is essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.